At a glance
- Originator University of Manchester
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 14 Nov 2003 Discontinued for Parkinson's disease (unspecified route)
- 06 Jul 1998 No-Development-Reported for Parkinson's disease (Unknown route)
- 10 Aug 1995 Investigation in Parkinson's disease (Unknown route)